Certara, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 08, 2023 at 04:33 pm
Share
Certara, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 85.58 million compared to USD 84.7 million a year ago. Net loss was USD 48.97 million compared to net income of USD 3.94 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to basic earnings per share from continuing operations of USD 0.03 a year ago. Diluted loss per share from continuing operations was USD 0.31 compared to diluted earnings per share from continuing operations of USD 0.02 a year ago.
For the nine months, sales was USD 266.33 million compared to USD 249.01 million a year ago. Net loss was USD 42.9 million compared to net income of USD 5.56 million a year ago. Basic loss per share from continuing operations was USD 0.27 compared to basic earnings per share from continuing operations of USD 0.04 a year ago. Diluted loss per share from continuing operations was USD 0.27 compared to diluted earnings per share from continuing operations of USD 0.03 a year ago.
Certara, Inc. is a provider of biosimulation technology and solutions for using Model-Informed Drug Development in the global biopharmaceutical industry. It is focused on producing medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its customers include life sciences companies of all sizes along with contract research organizations, academic institutions, and global regulators. Its software and service are used by approximately 2,400 biopharmaceutical companies and academic institutions across 66 countries, including 38 of the top 40 biopharmaceutical companies. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland, Egypt, and the United Kingdom.